Related Experiment Video
Updated: Feb 27, 2026
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.7K
Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.
Luyao Chen1,2, Yongpeng Xie3, Xintao Li1
1Department of Urology, Chinese PLA General Hospital, Beijing.
Oncotargets and Therapy
|June 28, 2017
Summary
High insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression indicates a poor prognosis in most solid tumors. IMP3 shows potential as a valuable prognostic biomarker for guiding clinical decisions in cancer care.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Research
Background:
- Previous studies on the prognostic role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in various cancers yielded inconsistent results.
- A need exists to clarify the prognostic value of IMP3 in human solid tumors.
Purpose of the Study:
- To conduct a systematic review and meta-analysis to evaluate the prognostic significance of IMP3 in human solid tumors.
- To consolidate existing evidence regarding IMP3 expression and patient survival outcomes.
Main Methods:
- A systematic literature search was performed across PubMed, Embase, Web of Science, and Cochrane Library databases (up to April 2016).
- Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for survival outcomes were calculated using STATA 12.0 software.
Main Results:
- The meta-analysis included 53 studies with 8,937 patients.
- High IMP3 expression was significantly associated with worse overall survival (OS) (HR = 2.08, 95% CI: 1.80-2.42, P<0.001).
- This association was consistent across various survival endpoints (CSS, DFS, RFS, PFS, MFS) and specific cancer types including RCC, lung, oral, urothelial, HCC, colorectal, pancreatic, gastric, and ICC.
Conclusions:
- Elevated IMP3 expression is linked to a poor prognosis in the majority of solid tumors.
- IMP3 is identified as a potentially valuable prognostic factor.
- IMP3 may serve as a promising biomarker to aid clinical decision-making in solid tumor management.
